WALTHAM, Mass., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (“the Company”) today provided an update on injection kits supplied by Apellis and an update on the rare ...

Credit: Apellis. Syfovre is indicated for the treatment of geographic atrophy secondary to age-related macular degeneration. Apellis announced that as part of its investigation into real-world safety ...

More than 100,000 vials have been distributed/administered between real world and clinical trials; since last update, confirmed one additional event of retinal ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Apellis is exclusively distributing injection kits with ...